Sandoz And AbbVie Biosimilar Humira Settlement: What Does It Mean?

Sandoz has become the latest firm to sign a settlement agreement over biosimilar Humira with AbbVie, heralding imminent launch in Europe. In the US, it will hold off launching until September 2023.

Greyhounds
Starter's orders - but who will be fast out of the traps? • Source: Shutterstock

Sandoz International GMBH has settled all patent litigation with AbbVie Inc. over its biosimilar version of the latter's Humira (adalimumab), the world's best-selling medicine. The agreement will see Sandoz paying royalties and launching Hyrimoz, its biosimilar of the TNF inhibitor, in Europe this year and in the US in September 2023. Sandoz's deal comes after three other companies have already signed similar agreements with AbbVie.

The deal gives Sandoz a non-exclusive licence to AbbVie's Humira IP from Oct. 16 in most EU countries and other...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Legal & IP

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.